A novel complex regulates cardiac actin gene expression through interaction of Emb, a class VI POU domain protein, MEF2D, and the histone transacetylase p300 by Molinari, Susanna et al.
MOLECULAR AND CELLULAR BIOLOGY, Apr. 2004, p. 2944–2957 Vol. 24, No. 7
0270-7306/04/$08.000 DOI: 10.1128/MCB.24.7.2944–2957.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
A Novel Complex Regulates cardiac actin Gene Expression through
Interaction of Emb, a Class VI POU Domain Protein,
MEF2D, and the Histone Transacetylase p300
S. Molinari,1 F. Relaix,2 M. Lemonnier,2 B. Kirschbaum,3 B. Scha¨fer,4 and M. Buckingham2*
CNRS URA 2578, Department of Developmental Biology, Pasteur Institute, 75724 Paris Cedex 15, France2;
Dipartimento di Scienze Biomediche, Universita` degli studi di Modena e Reggio Emilia, 41100 Modena,
Italy1; Aventis Pharma, D-65926 Frankfurt am Main, Germany3; and Department
of Pediatrics, University of Zurich, CH-8032 Zurich, Switzerland4
Received 12 August 2002/Returned for modification 23 October 2002/Accepted 6 January 2004
Expression of the mouse cardiac actin gene depends on a distal enhancer (7 kbp) which has been shown,
in transgenic mice, to direct expression to embryonic skeletal muscle. The presence of this distal sequence is
also associated with reproducible expression of cardiac actin transgenes. In differentiated skeletal muscle cells,
activity of the enhancer is driven by an E box, binding MyoD family members, and by a 3 AT-rich sequence
which is in the location of a DNase I-hypersensitive site. This sequence does not bind MEF2 proteins, or other
known muscle transcription factors, directly. Oct1 and Emb, a class VI POU domain protein, bind to consensus
sites on the DNA, and it is the binding of Emb which is important for activity. Emb binds as a major complex
with MEF2D and the histone transacetylase p300. The form of Emb present in this complex and as a major
form in muscle cell extracts is longer (80 kDa) than that previously described. These results demonstrate the
importance of this novel complex in the transcriptional regulation of the cardiac actin gene and suggest a
potential role in chromatin remodeling associated with muscle gene activation.
Cardiac actin is a major actin isoform not only in the heart
but also in developing skeletal muscle (37). Like other genes
transcribed specifically in striated muscle, regulation of the
cardiac actin gene depends not only on a proximal promoter
but also on enhancer sequences, which target distinct sites of
expression. DNase I-hypersensitive site analysis with cells of
the C2 skeletal muscle cell line led to the identification of two
such sequences at 7 and 5 kbp upstream of the mouse
cardiac actin gene (2). In both cases, a DNA fragment of
several hundred kilobases around the site was shown to act as
an enhancer in differentiated muscle cells. In transgenic mice
(3), the proximal promoter can direct reporter gene expression
to cardiac and skeletal muscle in the embryo, but transgenic
lines tend to show weak or undetectable expression and the
adult heart is negative. In contrast, when an upstream genomic
sequence which includes both hypersensitive sites is present,
high-level, reproducible expression, which resembles that of
the endogenous gene, is shown by all transgenic lines analyzed.
Transgenic lines with 5 kbp of upstream sequence show ex-
pression in embryonic striated muscle and in adult cardiac
muscle, but only in about 50% of lines. The 7-kbp enhancer
alone, with the proximal promoter, directs reliable transgene
expression to embryonic skeletal muscle, suggesting that this
sequence acts in vivo as a skeletal muscle enhancer and that its
presence facilitates transcription of the transgene at different
DNA insertion sites. Displacement of this region of DNA, due
to a 5 duplication of the endogenous cardiac actin gene, per-
turbs its transcription in both skeletal and cardiac muscle of
BALB/c mice, which have abnormally low levels of cardiac
actin (18, 19). Molecular analysis of the C2 muscle cell line
showed that activity depends critically on one of several E
boxes, which proved to be the target of myogenic regulatory
factors of the MyoD family, conferring skeletal muscle speci-
ficity on the enhancer, and on a second 3 AT-rich region,
which did not correspond to a canonical consensus sequence
for transcription factors known to be important in myogenesis
(2). This sequence is in the location of the DNase I-hypersen-
sitive site and is of interest in regulating access to the locus.
Although other muscle enhancers have been identified on
the basis of DNase I hypersensitivity, such as those of the
M-creatine phosphokinase (M-CPK) (24) or myosin MLC1F/3F
(26) genes, very little is known about sequences which may
regulate the accessibility of genes to muscle-specific transcrip-
tion. A sequence in the vicinity of the mouse desmin gene
which corresponds to a DNase I-hypersensitive site has been
shown to have properties of a locus control region when ana-
lyzed by transgenesis, but its molecular regulation is not yet
clear (48). If there are almost no examples of bona fide muscle
locus control regions comparable to those described for the
globin genes (61), there are now a number of reports which
implicate muscle transcription factors in chromatin remodel-
ing. The myogenic determination factors Myf5 and MyoD (see
reference 5), when transfected into nonmuscle cells, affect the
accessibility of muscle genes, such as M-CPK, hence facilitating
myogenic conversion (20).
MyoD has been shown to interact with p300/CBP (16, 39, 45,
49, 66) and PCAF (47) histone transacetylases, which, by mod-
ifying nucleosome structure, render chromatin more accessible
to transcription (57). The interaction with p300 involves se-
quence motifs which overlap with those implicated in the phe-
nomenon described by Gerber et al. (20). In transitory-trans-
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fection experiments, the presence of p300 or PCAF increases
the transactivation of a muscle reporter gene by MyoD, in this
situation acting as a muscle differentiation factor; inhibitor
experiments with muscle cells suggest that PCAF intervenes at
the onset of differentiation, while p300/CBP affects the later
activation of muscle structural genes and enzymes (44, 47). In
addition to a potential effect on chromatin structure, these
histone transacetylases directly acetylate MyoD, increasing its
transcriptional activity (43, 51). Members of the myocyte en-
hancer factor 2 (MEF2) family of transcription factors, which
play a critical role in the activation of many muscle genes (4),
have also been reported to interact with p300/CBP with en-
hancement of skeletal (50) and cardiac (55) muscle gene tran-
scription in cultured cells.
In contrast to histone transacetylases, histone deacetylases
(HDACs) prevent transcription by rendering chromatin inac-
cessible (59). Class II HDACs, such as HDAC IV, interact with
MEF2 transcription factors and render them inactive (15, 29,
31, 38; also see reference 35). This effect is probably also due
to repression domains in the HDAC protein. HDAC1 can
interact directly with MyoD, and this association, which occurs
in undifferentiated myoblasts, renders MyoD transcriptionally
inactive (32). The interaction between MEF2 and class II
HDACs can be modulated by signaling pathways which phos-
phorylate the latter, leading to their nuclear export with con-
sequent release of MEF2 for transcriptional activation (35).
Another form of modulation may be exerted by cofactors
which facilitate the recruitment of histone modifying enzymes
to form complexes with myogenic regulatory factors. An ex-
ample is provided by GRIP-1 (7), which has intrinsic histone
transacetylase activity and also acts as a coactivator by recruit-
ing p300 and PCAF. GRIP-1 can form a complex with MEF2
and with the MyoD family member myogenin to enhance the
transcriptional activation of muscle genes during muscle cell
differentiation.
Investigation of the 3 region of the enhancer located at
7 kbp upstream of the mouse -cardiac actin gene led to the
identification of a novel protein complex which binds to the
sequence. Interference with its binding compromises enhancer
activity. The complex contains a longer isoform of the class VI
POU factor, Emb (42), which binds to the DNA and is asso-
ciated with the myogenic factor MEF2D. The histone trans-
acetylase p300 is also present as part of the Emb-MEF2D
complex. This finding reveals Emb as a participant in muscle
gene regulation. The potential role of this complex in poten-
tiating myogenic expression of the cardiac actin gene is dis-
cussed.
MATERIALS AND METHODS
Cell culture. C2/7 is a skeletal muscle cell line subcloned from the original C2
cell line derived from C3H mice (64). C2/7 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) containing 20% fetal calf serum at low
density and, when approaching confluence, induced to differentiate with
DMEM–2% fetal calf serum.
Transfection experiments. Cells were grown in 60-mm-diameter dishes to 50%
of confluence and transfected by the calcium phosphate method (2) with 10 g
of CAT reporter plasmid and 1 g of a plasmid where the luciferase reporter
gene is under the control of the Rous sarcoma virus promoter (RSV Luciferase)
to normalize for transfection efficiency. Precipitates were allowed to form for 30
min at room temperature. Cells were incubated with the DNA-calcium phos-
phate precipitates overnight (o/n), rinsed twice with DMEM the day after, and
induced to differentiate over 48 to 72 h. Cells were then scraped in 100 l of a
solution containing 40 mM Tris (pH 7.5), 150 mM NaCl, and 1 mM EDTA; 30%
of the extract was used for the luciferase assay and up to 30% for the CAT assay.
CAT assay. Three to four independent transfections were carried out for each
point. CAT assays were carried out by the butyryl coenzyme A method (53). The
cell extracts were incubated in a 100-l reaction volume of 250 mM Tris-Cl (pH
7.5) in the presence of 0.53 mM butyryl coenzyme A (B1508; Sigma) and 0.04
Ci of [14C]chloramphenicol (50 to 60 mCi/mmol, CFA 754; Amersham) for 1 h
at 37°C. The butyrylated products were extracted with 200 l of tetramethylpen-
tadecane-xylene (2:1), and the extracted radioactivity was measured in an organic
counting scintillant. Counts were normalized to the corresponding luciferase
assay data.
Luciferase assay. Samples were diluted to a 100-l final volume with LUC
buffer (250 mM Tris-phosphate [pH 7.5], 8 mM MgCl2, 1 mM EDTA, 2 mM
dithiothreitol). Luciferase activity was measured with a luminometer (LUMAT
LB 9501; Berthold), which injects 100 l of reaction mix (0.2 mM luciferine
[sodium] and 4 mM ATP in LUC buffer).
Mutagenesis. Point mutations in the AT-rich sequence were obtained by
oligonucleotide-mediated mutagenesis with the Transformer TM site-directed
mutagenesis kit (Clontech) with the selection primer Trans Oligo TM AflIII/
GblII (Clontech). For this purpose, the 3 PstI fragment (360 bp) from the distal
enhancer of the cardiac actin gene (2) was cloned into the plasmid vector
pBluescript SKII. The selection primer and the 35mer primers carrying the
desired mutation in the AT-rich sequence were phosphorylated in vitro, and a
200-fold excess of the primers was annealed to the denatured template DNA,
which was then extended by T4 DNA polymerase and ligated with the T4 DNA
ligase. The resulting DNA was digested with the restriction enzyme AflIII and
transformed in MutS Escherichia coli bacterial cells. The plasmid DNA was
extracted and analyzed before introduction of the mutated DNA into XL1 Blue
E. coli cells. The distal enhancer with the point mutations introduced into the
AT-rich sequence was excised with HindIII and XbaI from the pBluescript SKII
vector and cloned into the HindIII/XbaI sites of the pBLCAT3 plasmid, 5 to the
proximal promoter of the cardiac actin gene.
Nuclear extracts and GMSAs. C2/7 cells were grown in 15-cm-diameter dishes
and taken at the early myoblast stage or at the myotube stage. Nuclear extracts
were prepared using a modification of the method of Dignam et al. (12, 17).
Nuclear extracts were divided into aliquots and conserved in liquid nitrogen. The
protein concentration was measured by using the method of Bradford (Bio-Rad
assay kit). The RsaI-PstI AT-rich 3 fragment (76 bp) of the distal enhancer was
cloned into the EcoRV-PstI sites of the Bluescript plasmid vector. To use the
AT-rich fragment as a probe in a gel electrophoresis shift assay (GMSA), the
DNA fragment was obtained by HindIII-XbaI digestion of the Bluescript plas-
mid vector and labeled by end filling using [-32P]dTTP and [-32P]dCTP. The
IPOCT probe and the Emb binding site were obtained by annealing the com-
plementary in vitro-synthesized oligonucleotides and labeled with [-32P]ATP,
using polynucleotide kinase. The sequences of the sense strand of the IPOCT
probe and of the Emb binding site were as follows: IPOCT, 5-CCTAATCCA
CTGCAATAAGCAAATATTTCTATAATGGGAT-3; Emb/mPOU, 5-CAG
CTCATTATGATAATGAGGGGG-3 (63). GMSAs were performed in a total
volume of 15 l containing 2 g of poly(dI-dC), 4 g of nuclear extract protein,
1.5 l of gel shift buffer (50 mM Tris [pH 8.0], 5 mM dithiothreitol, 5 mM EDTA,
250 mM NaCl, 10% Ficoll) and 1 ng of labeled DNA probe (6). The assay
mixture was incubated at room temperature for 20 min and then run in a 5%
nondenaturing polyacrylamide gel (acrylamide/bisacrylamide ratio, 49:1) in 0.5
Tris-borate-ETDA. After the run was completed, the gel was fixed with a solu-
tion containing 10% ethanol and 10% acetic acid for 10 min, dried on a 3MM
paper sheet (Whatman), and exposed to MP autoradiography film (Amersham).
For the supershift experiments, mPOU (62), Oct1 (52), MEF2A, -B, and -D (22),
and HDAC4 (38) antibodies were used. Oct1, MEF2, and HDAC4 antibodies
were kind gifts of W. Schaffner, R. Prywes, and T. Kouzarides, respectively. p300
monoclonal antibody (NM11) was supplied by Pharmingen. The competition
experiments were performed by diluting the labeled probe with a 50- to 100-fold
molar excess of cold competitor double-strand oligonucleotides. The sequences
of the sense strands of the oligonucleotides used as competitors were as follows:
muscle creatine phosphokinase (M-CPK) MEF2 site, 5-AAGCTCGCTCTAAA
AATAACCCTGTCCCTGGT-3; M-CPK Mhox site, 5-GGTTATAATTAACC
CAG-3; Troponin I AT-rich site, 5-CGCAGTATATTTAGTCTG-3 (13); H2B
Oct1 site, 5-CGAGCTTCACCTTATTTGCATAAGCGATTG-3 (54).
Copper-orthophenanthroline footprinting. To asymmetrically label the coding
strand of the AT-rich sequence, the distal enhancer cloned into the HindIII/XbaI
sites of pBluescript was first digested with XbaI by end filling and then cut with
RsaI, and the labeled fragment was purified by gel electrophoresis, followed by
electroelution of the DNA. The noncoding strand was labeled by end filling of
the HindIII-SmaI AT-rich fragment. The asymmetrically labeled probes were
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incubated with C2 nuclear extracts as for a gel shift experiment, with the binding
reactions scaled up threefold. The binding reactions were run in a nondenaturing
polyacrylamide gel. After electrophoresis, the gel was equilibrated for 30 min in
300 ml of 50 mM Tris-Cl (pH 8.0). Cleavage of the DNA was initiated by adding
30 ml of 2 mM 1,10-phenanthroline, 0.45 mM copper sulfate, and 30 ml of 58
mM 3-mercaptopropionic acid. After 10 min, cleavage was stopped by adding 30
ml of copper orthophenanthroline “stop” solution (28 mM 2,9-dimethyl 1,10-
phenanthroline). After the reaction, the gel was extensively washed in distilled
water and then exposed to an autoradiographic film. The bands corresponding to
DNA-protein complexes were cut out, and the DNA was eluted in a solution
containing 500 mM ammonium acetate, 1 mM EDTA, 0.1% sodium dodecyl
sulfate (SDS), and 10 mM MgCl2 at 37°C o/n. The eluted DNA was precipitated
by adding 10 g of glycogen and two volumes of cold ethanol. The products of
the footprinting reaction were loaded onto a 9% denaturing sequencing gel. An
AG Maxam Gilbert sequencing reaction was carried out on the coding and
noncoding strands of the AT-rich fragment (34), and the product of the reaction
was loaded beside the footprinting reaction. The sequencing gel was dried and
quantitatively analyzed using a phosphorimager.
Biotinylated probe pulldown. The biotinylated AT-rich probe was obtained by
PCR using the following primers (Sigma Genosys): Direct, 5-ACTTTTCAAT
GTTTCCTAATC-3; Reverse, 5-GCAGATCTGAACCAGCC-3. The control
probe, obtained by PCR, contains a mutation in this sequence which removes
most Emb binding by introducing G residues in the second half of the AT-rich
site to give CTGTGATGGG.
The direct primer was biotinylated at the 5 end. The PCR was conducted with
Pfu DNA polymerase (Stratagene); after 12 amplification cycles, the product was
purified by polyacrylamide gel separation followed by electroelution of the DNA
from the gel. Dynabeads M-280 streptavidin beads (Dynal Inc., Lake Success,
N.Y.) were prepared by three washes in phosphate-buffered saline (pH 7.4)
containing 0.1% bovine serum albumin and two washes with 10 mM Tris (pH
7.5)–1 mM EDTA–1 M NaCl (TEN). After each wash, the beads were collected
with a Dynal magnetic particle concentrator. To immobilize the DNA on the
beads, 800 g of biotinylated AT-rich probe was incubated with 250 l of
magnetic beads in 1 ml of TEN at room temperature for 20 min. After three
washes with TEN and two washes with the GEMSA buffer containing 0.01%
Triton X-100 and 2.5 g of bovine serum albumin/l, the beads were incubated
with 50 g of nuclear extract protein in 100 l of gel shift buffer (see “Nuclear
extracts and GMSAs”) containing 0.01% Triton X-100, 2.5 g of bovine serum
albumin/l, and 4 g of poly(dI-dC) for 20 min at room temperature, under
gentle rotation. Proteins bound to the beads were separated with the magnetic
particle separator after the unbound proteins had been washed away. The beads
were washed three times with 1 ml of 0.5 gel shift buffer containing 0.01%
Triton X-100 and 1 g of poly(dI-dC). The beads were resuspended in 50 l of
2 SDS gel loading buffer, boiled for 5 min, and centrifuged. The supernatant
was analyzed by Western blotting.
Western blot analysis. For the analysis of nuclear extracts, 10 g of nuclear
proteins obtained from proliferating or differentiated C2 cells were diluted in 1
SDS gel loading buffer (50 mM Tris-Cl [pH 6.8], 100 mM dithiothreitol, 2% SDS,
0.1% bromophenol blue, 10% glycerol) and run in an SDS–8% polyacrylamide
gel (5% to detect p300). After electrophoresis the proteins were transferred to a
polyvinylidene difluoride membrane (Amersham). Filters were blocked by incu-
bation with PBST (phosphate-buffered saline containing 0.1% Tween 20), with
added 5% lowfat dry milk, for 1 h and then incubated with the primary antibodies
(1:1,000) for 2 h. The following antibodies were used: polyclonal anti-mPOU
antibody and the corresponding preimmune serum, polyclonal anti-MEF2D,
polyclonal anti-HDAC4, and monoclonal NM11 P300 (Pharmingen). Filters
were extensively washed in PBST and then incubated with horseradish peroxi-
dase-conjugated secondary antirabbit and antimouse antibody (Amersham) (1:
5,000) for 1 h. After further extensive washes with PBST, antigen-antibody
complexes were visualized with the enhanced chemiluminescence kit (ECL Plus)
from Amersham.
ChIP assay. The chromatin immunoprecipitation (ChIP) protocol was adapt-
ed from the method of Soutoglou et al. (56). C2C7 muscle cells (3  108) at
different stages of differentiation were fixed with 1% formaldehyde at room
temperature for 10 min. The cross-linking was stopped by addition of glycine at
a 0.125 M final concentration for 5 min. Cells were detached in phosphate-
buffered saline and pelleted by centrifugation at 1,000 rpm for 5 min at 4°C in a
Sigma 4-15 centrifuge. The cells were resuspended in 5 volumes of lysis buffer
(0.3 M sucrose, 10 mM HEPES-KOH [pH 7.9], 10 mM KCl, 2 mM MgCl2, 1 mM
EGTA, 0.5 mM dithiothreitol, 0.3% NP-40, 0.5 mM phenylmethylsulfonyl fluo-
ride) and lysed with a Dounce homogenizer. Nuclei were pelleted by centrifu-
gation at 2,000 rpm for 5 min at 4°C in a Sigma 4-15 centrifuge and resuspended
in 4 ml of sonication buffer (50 mM HEPES-KOH [pH 7.9], 140 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 0.5 mM phenyl-
methylsulfonyl fluoride, and a protease inhibitors tablet [Complete; Sigma]).
Nuclei were sonicated for 4 min at 4°C to reduce the DNA length to between 500
and 2,000 bp. After the sonication, the chromatin was separated from nuclear
debris by centrifugation at 14,000 rpm for 30 min at 4°C in a Sigma 4-15
centrifuge, and 10 optical density units at 260 nm were used for the immuno-
precipitation step. Prior to immunoprecipitation, the chromatin was precleared
for 1 h at 4°C with 5 l of preimmune antibody and a 1/10 volume of unblocked
protein A-Sepharose (Sigma). The precleared chromatin was incubated o/n with
5 l of primary antibody. Immune complexes were immunoprecipitated with a
1/10 volume of protein A-Sepharose previously blocked with 0.1 mg of sonicated
salmon sperm DNA/ml and 1 mg of bovine serum albumin/ml and then washed
twice with sonication buffer, twice with sonication buffer containing 500 mM
NaCl, twice with buffer B (20 mM Tris-HCl [pH 8.0], 250 mM LiCL, 1 mM
EDTA, 0.5% Na-deoxycholate, 0.5% NP-40, 0.5 mM phenylmethylsulfonyl flu-
oride) and twice with TE (10 mM Tris-HCl [pH 8.0], 1 mM EDTA) buffer. The
immunoprecipitated DNA-protein complexes were eluted in 400 l of elution
buffer (50 mM Tris-HCl [pH 8.0], 1 mM EDTA, 1% SDS) at 65°C for 20 min.
NaCl to a final concentration of 200 mM was added to the eluted DNA-protein
complexes, and the cross-linking was reversed by incubation at 68°C o/n. Proteins
were digested by addition of 100 l of 5 proteinase K buffer (50 mM Tris-HCl
[pH 7.5], 250 mM NaCl, 5 mM EDTA, 5% SDS) and 0.1 mg of proteinase K/ml
at 37°C o/n. Following a phenol-chloroform (1:1) extraction, the DNA was
precipitated with 0.3 M Na acetate (pH 5.2) and 2.5 volumes of ethanol at 20°C
o/n. The immunoprecipitated DNA was dissolved in 100 l of distilled water and
digested with 3 g of DNase-free RNase at 37°C for 30 min.
The immunoprecipitated chromatin (12 l) was analyzed by real-time PCR
using the SYBR GREEN system (Abiprism 7000; Applied Biosystems). The
chromatin was subjected to 45 amplification cycles. For the analysis, the follow-
ing oligonucleotides were used to amplify the AT-rich sequence of the distal
enhancer of the cardiac actin gene: 5-ACCAGCCTACATCCCATTATAGAA
A-3, act. forward; 5-TCCTAATCCACTGCAATAAGC-3, act. reverse.
To quantify the product, a series of dilutions of the corresponding input DNA
was amplified with the same oligonucleotides. Enrichment in the ChIP experi-
ments was estimated as the quantity of actin DNA immunoprecipitated in the
presence of mPOU (Emb), p300, or MEF2D antibodies. Controls were carried
out with unrelated antibodies, to -galactosidase, to hemoagglutinin, or to the
CAAT box binding factor NFYB.
As a further control, the precipitated chromatin was amplified with two oli-
gonucleotides that amplify an enhancer region of the liver-specific phenylalanine
hydroxylase (PAH) gene (45). The sequence of the oligonucleotides used to
amplify the PAH sequence are the following:5-CAAAATGGTGCTGTATC
TCTGATATTC-3, PAH forward; 5-GGCACCAACTTCCTCTTTGAGT-3,
PAH reverse.
The p300 antibody used for the immunoprecipitation was from Santa Cruz (sc
585X). The NFYB antibody used as a control was a gift from R. Mantovani.
Polyclonal -galactosidase antibody was from Molecular Probes, and polyclonal
hemoagglutinin antibody was from Sigma.
The chromatin immunoprecipitated from proliferating C2 cells has been also
subjected to standard PCR with the same oligonucleotides used to amplify the
actin sequence in the real-time PCR. The reaction was carried out with 1/10 of
the immunoprecipitation product, 0.5 M (each) primer, 100 M deoxynucleo-
side triphosphates, 0.4 l of Advantage Taq polymerase (Clontech), and 1 l of
[32P]dATP (Amersham) in a 25-l final reaction volume. After 30 cycles of
amplification, all the reaction was separated on a 10% polyacrylamide gel. The
gel has been dried and subjected to autoradiography.
RESULTS
Protein complexes binding to the 3 AT-rich fragment from
the distal enhancer of the cardiac actin gene. As shown pre-
viously, the activity of the distal enhancer of the mouse cardiac
actin gene in skeletal muscle cells depends on the presence of
an E box which binds myogenic factors and on an AT-rich
sequence (76 bp) located at the 3 end (2, 3). The MEF2 family
of transcription factors, involved in muscle gene regulation,
bind to a C/TTA(A/T)4TAG/A consensus sequence (21; also
see reference 4). This is not present as such in the 3 AT-rich
region. There is a consensus binding site for Oct1 (23, 57)
with one mismatch in the central octamer core (AAGCA
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AAT instead of ATGCAAAT) and conserved core flanking
sequences. Downstream of the Oct1 site there is a second AT-
rich sequence (ATTT(N)3TAAT) which is similar to a home-
odomain transcription factor binding site, shown to be optimal
for human mPOU, another POU domain protein (63), identi-
fied as Emb in the mouse (42). These consensus sites are in-
dicated in Fig. 1A.
In order to identify binding activities with the 3 AT-rich
fragment, we performed gel shift experiments using nuclear
extracts from the C2 skeletal muscle cell line. Incubation of the
76-bp fragment with myoblast or myotube nuclear extracts led
to the formation of several DNA-protein complexes (a to h;
Fig. 1B). The complexes a and b were clearly competed by a
50-fold excess of cold probe but not by an equivalent molar
excess of an unrelated binding site (not shown). These com-
plexes were seen with extracts from muscle cell lines and em-
bryonic muscle (not shown).
Characterization of the DNA-protein contacts in complexes
a and b by DNA footprinting. To further analyze the complexes
a and b, we examined the nucleotides contacted by the DNA
binding activities in C2 nuclear extracts. The copper ortho-
phenanthroline in situ footprinting strategy was used, since in
the presence of several DNA-protein complexes it allows anal-
ysis of DNA-protein contacts in the complex of interest. Figure
2 shows the footprinting profiles obtained with the labeled
coding and noncoding strands, respectively, of the 3 AT-rich
fragment involved in complex a. The nucleotides contacted in
complex b are identical (not shown), suggesting that the bigger
complex a may be an aggregate of b or involve additional pro-
teins which do not affect the sites of DNA contact. A schematic
FIG. 1. (A) Schematic representation of the distal enhancer of the cardiac actin gene, showing the E box, which is essential for activity and the
sequence of the AT-rich 3 region. This contains consensus sites for Oct1 and Emb, as indicated. The shorter probe, IPOCT, used in subsequent
experiments, is shown. (B) Gel shift experiment using the entire AT-rich fragment (76 bp) as probe. The nuclear extracts used were from C2
myoblasts (lanes 2 and 4) and myotubes (lane 3). The main DNA-protein complexes are indicated by arrows and letters (a to h). A self-competition
experiment is shown, where a 50-fold excess of cold probe was added to the binding reaction (lane 4). In lane 1 the migration of the free probe
is shown.
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representation based on phosphorimager quantification of the
footprint is shown in Fig. 3A. The putative Emb binding site is
contacted on the coding strand. A protection is observed on
the 5 side of the Oct1 site and on the 5 Emb half-site, ATTT,
extending more weakly with this consensus. Hypersensitivity is
observed on the other side of the Emb site on the coding strand
and is also clearly evident on the noncoding strand, where
protection is seen on the 3 end of the Oct1 consensus.
Characterization of cis-acting elements which affect activity
of the 3 AT-rich element. The 3 AT-rich fragment by itself, as
a single copy or in multimerized form, is not able to enhance
the activity of the cardiac actin promoter in driving reporter
gene expression (data not shown). We therefore tested the
effect of mutations, based on the results of the footprinting
experiment, in the context of the entire distal enhancer (360
bp), with the proximal promoter (680 bp) of the mouse cardiac
actin gene. Results of reporter CAT activity, shown in Fig. 3B,
are expressed relative to the construction with the wild type
(WT) enhancer. Mutation of the 3 part of the putative Emb
site (Mut6) results in a significant reduction (70%) of activity.
Mutating other nucleotides did not lead to significant de-
creases in the activity of the enhancer, with the possible ex-
ception of Mut3, which affects the 5 part of the Emb site and
consistently resulted in a minor reduction. Mutating the puta-
tive Oct1 site to a perfect Oct1 consensus (Mut7), if anything,
resulted in a small increase in activity, and mutations which
destroy the Oct1 consensus (Mut2) had no significant effect.
Mutations in the region of hypersensitivity 3 to the Emb
consensus (Mut4 and Mut5) and in a putative PEA3 site
(Mut1) had no effect.
The influence of mutations which affect distal enhancer ac-
tivity on the binding of protein complexes. The 3 AT-rich
fragment is involved in the formation of several DNA-protein
complexes, as seen in gel shift experiments with nuclear ex-
tracts from the C2 muscle cell line. We tested whether the
presence of the mutations in the 3 fragment which influence
the activity of the distal enhancer affects these complexes (Fig.
4). The mutation (Mut6) which reduces the activity by 70%
leads to a marked reduction in band a and loss of band b,
compared with effects of WT sequence or Mut5. Band d is also
somewhat reduced. Mut3, which has a small negative effect on
activity, also results in a diminution of bands a and b. These
mutations affect the Emb consensus sequence and suggest that
the Emb POU domain protein is involved in complexes a and
b. Mut7, which gives a minor increase in activity, results in
increased intensity of bands c and d, which may be associated
with Oct1 binding since this mutation improves the Oct1 con-
sensus.
Characterization of the proteins present in the complexes
binding to the 3 AT-rich fragment. In order to establish which
proteins are present in the complexes formed with the 3 AT-
rich fragment, competition experiments were performed with
oligonucleotides to the consensus binding sites and with anti-
bodies to transcriptional factors suspected of binding to the
fragment. Since Emb is a candidate, the presence of the pro-
tein was verified in C2 muscle cell extracts by Western blot
analysis, using an antibody directed against the human homo-
logue, mPOU (62). This reveals a protein of about 80 kDa,
which is not recognized by the preimmune serum (Fig. 5A). It
is present in both myoblast and myotube extracts. An oligonu-
cleotide containing the proposed binding site for Emb/mPOU
(ATTA. . .TAAT) (59) was used as a probe in gel shift exper-
iments with myotube nuclear extracts. This forms two com-
plexes, one of which is supershifted by an Oct1 antibody (52)
and the other of which is disrupted by the mPOU antibody
(Fig. 5B). Oct1 is abundant in C2 extracts, as seen on Western
blots (data not shown) (also see reference 10); the band shift
results show that Emb is present, but at a lower level, as indi-
FIG. 2. An example of a footprinting experiment using the copper
orthophenanthroline method. The analysis shown is with the DNA-
protein complex a, obtained on incubation of C2 myoblast nuclear
extracts with the AT-rich fragment; the same profile of protection was
obtained with complex b (not shown). Both the coding strands and the
noncoding strands were analyzed. To identify precisely the protected
nucleotides, a sequencing reaction with the same fragment obtained by
a Maxam Gilbert reaction for nucleotides A and G (AG) was run at
the same time. The sequence in the region of the protected area is
shown, and protected nucleotides are encircled.
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cated by the relative intensities of binding to the Emb/mPOU
sequence, which also has affinity for Oct1 (1).
In gel shift experiments with C2 muscle cell extracts and the
3 AT-rich fragment, the mPOU antibody disrupts complexes a
and b (Fig. 6A). In competition experiments with a 50-fold
excess of the Emb/mPOU consensus sequence (ATTA. . .
TAAT), bands a and b are considerably reduced (Fig. 6B).
These results show that Emb binds to the 3 AT-rich fragment
in complexes a and b. There is also competition with band d; an
Oct1 antibody reduced band d (Fig. 6A), which was competed
with an Oct1 consensus binding site (ATGCAAAT) (Fig. 6B).
In this experiment, band c, which varies between extracts, was
not visible. The presence of other proteins able to bind AT-rich
regions was also tested. The MEF2 family of transcription
factors (4) bind to an AT-rich consensus. A MEF2 consensus
oligonucleotide, as present in the enhancer of the M-CPK gene
(21), does not compete with complexes a and b (Fig. 6B) or
indeed interfere with other bands seen with the 3 AT-rich
fragment. However, an antibody against the MEF2D isoform
(22) specifically disrupts band b, while antibodies to MEF2A
and MEF2B have a more minor effect on this band (Fig. 6A).
The Mhox protein binds to an AT-rich consensus (TTATAA
TTAA) which has been shown also to bind MEF2 and Oct1
(10); again there is no competition of bands a and b and a
minor effect on band d (Fig. 6B). This is also the case for the
AT-rich sequence (TATATTTA) in the Troponin I promoter,
which has been shown to bind MEF2A and Oct1 (13). Since we
are using muscle cell extracts, the presence of myogenic regu-
latory factors, MyoD, myogenin, and Myf5, in the complexes
was also checked. There is no E-box consensus (CANNTG) in
the 3 AT-rich fragment, but these factors can form complexes
with MEF2 (4) without binding directly to DNA. Antibodies to
these proteins had no effect on the DNA-protein complexes
seen on gel shift (results not shown), and we conclude that this
family of myogenic regulatory factors is not involved.
Further gel shift experiments were carried out with a shorter
40-bp fragment (IPOCT; Fig. 1A), which contains the Oct1
and Emb sites. This gives one major band migrating at the level
of band d, which is now competed by the Oct1 and Emb
consensus sequences (Fig. 6C). MHox also competes Oct1
binding, as observed previously (10). The Oct1 antibody shifts
the major complex, which is also partially disrupted by an
mPOU antibody. We conclude that this band corresponds to
Oct1 binding. In excess, the Emb consensus will compete for
Oct1 (see Fig. 5B), as seen also for band d in Fig. 6B. There is
also some interaction between the mPOU antibody and Oct1
(see Fig. 5B). The complex which migrates at the level of band
b is affected only by competition with the Emb consensus or
FIG. 3. Mutational analysis of the 3 AT-rich sequence. (A) Schematic representation of the protection profile obtained for the coding strand
of the 3 AT-rich sequence in the footprinting experiment, based on phosphorimager quantification of the autoradiograph. The baseline
corresponds to the intensity of the signal obtained for each nucleotide of the free probe. Each column represents the signal obtained for each
nucleotide in the complex. The protected areas correspond to the signals below the baseline. Both 5 and 3 to the protected region there are
hypersensitive areas. (B) The sequence of the AT-rich fragment as WT or containing mutations (Mut) is shown. The point mutations are in bold;
the nucleotides to be mutated were chosen on the basis of the footprinting profile and potential transcription factor binding sites. The functional
analysis of each point mutation is reported on the right. The effect of the WT or mutated enhancer (360 bp, including the active E box) with the
promoter (680 bp) of the cardiac actin gene on the expression of a CAT reporter gene was measured in transient transfections in C2 myotubes.
The activity of the WT enhancer was considered to be 100%.
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incubation with the mPOU antibody, confirming that it con-
tains Emb but not Oct1. As expected, the MEF2 consensus
does not compete complex b, but it is disrupted by the MEF2D
antibody. We conclude that complex b contains Emb and
MEF2D and complex d contains Oct1. The large complex a
does not form, under gel shift assay conditions, in the absence
of the region lying 3 to the Emb site. Under these conditions,
Oct1 binding to give complex d predominates.
The proteins present in complex a. The data presented in
Fig. 6 show that complex a contains Emb. It may also contain
MEF2D, like complex b, but unless there is disruption of the
complex this is difficult to assess at this level in the gel. The size
of complex a would suggest that other large proteins may be
associated with it. It has been shown that MEF2 can interact
with HDACs and also with the histone transacetylase CBP/
p300 (35). We therefore investigated whether these proteins
are present. Preincubation of C2 muscle cell nuclear extracts
with a p300 antibody resulted in a partial disruption of complex
a in a gel shift experiment (Fig. 7A). No disruption was seen
when an HDAC4 antibody was used. In order to characterize
better the nature of the complex, we adopted an alternative
strategy, based on the use of streptavidin-coated magnetic
beads to which the biotinylated 3 AT-rich sequence had been
bound. C2 nuclear extracts were incubated with the beads with
or without DNA. Gel shift analysis of the flow-through fraction
showed that in the presence of DNA, complexes (a to h) were
no longer present (Fig. 7B, lane 2), whereas with the control
beads (Fig. 7B, lane 3), without DNA, the gel shift profile was
similar to that with the nuclear extracts before passage over the
beads (Fig. 7B, lane 1). The eluted proteins were separated
on a denaturing polyacrylamide gel and analyzed by West-
ern blotting. Figure 7C (lane 2) shows that MEF2D, p300,
and mPOU antibodies detected bands, whereas no HDAC4
band was detectable. Figure 7D confirms that the complex is
specifically retained by the AT-rich sequence (lane 2), since
when this is mutated it no longer binds (lane 3). The amount
of MEF2D, as well as p300, indicates that it is also present in
the main complex a, as well as in the minor complex b, as seen
in band shift experiments. Relatively low levels of Emb were
detected by the mPOU antibody in this experiment, possibly
due to degradation during the elution procedure, reflecting
its relative instability (S. Molinari and M. Buckingham, un-
published data) compared to MEF2D/p300. Alternatively,
since the total disruption of complex a, when Emb binding is
prevented by an antibody (Fig. 6A), and the footprint (Fig. 2)
would suggest that DNA binding of MEF2D and p300 to the
3 AT-rich fragment goes through Emb, this protein may have
remained partially bound to the DNA and thus been less
efficiently eluted.
ChIP. In order to verify that the complex containing Emb,
MEF2D, and p300 also exists on the enhancer sequence of the
endogenous cardiac actin gene, we performed ChIP experi-
ments with antibodies to these proteins on sonicated chroma-
tin from muscle cells. The genomic DNA in the precipitated
FIG. 4. Gel shift experiments with C2 myoblast nuclear extracts using the AT-rich 3 fragment as a probe (WT) or the same fragment mutated
in the positions indicated in Fig. 3. The WT DNA fragment and the mutated DNA fragments were cloned into different restriction enzyme sites
of the polylinker of the cloning vector pBluescript, so they have slightly different sizes. Complexes indicated by letters and arrows are as shown
in Fig. 1.
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complex was analyzed by real-time PCR, using primers to
amplify the enhancer site. The results of such an experiment
with myoblast nuclear extract are shown in Fig. 8A, with the
cardiac actin regulatory sequence and with a control sequence
from the PAH gene, which is not expressed in skeletal mus-
cle. All three antibodies to mPOU, which recognizes Emb,
MEF2D, and p300, immunoprecipitate a complex with the
cardiac actin sequence, which is detectable at a lower amplifi-
cation frequency than the background level seen with the con-
trol sequence. In Fig. 8B, the sequence amplified by PCR after
chromatin immunoprecipitation is visualized by autoradiogra-
phy after gel electrophoresis, again demonstrating the forma-
tion of a complex with Emb, MEF2D, and p300. Histograms of
the results of such experiments, where the amplification with
the cardiac actin sequence has been corrected relative to the
control sequence (Fig. 8C), demonstrate that Emb, MEF2D,
and p300 form a complex on the site in the enhancer sequence
of the endogenous cardiac actin gene in myoblasts, confluent
cultures, and differentiated myotubes. It is striking that p300
gives much more enrichment of the -cardiac sequence in
myotubes when the -cardiac actin gene is actively transcribed.
This may reflect the involvement of p300 in complexes at other
sites, such as the E box, on the enhancer sequence.
DISCUSSION
Analysis of the proteins which bind to the 3 AT-rich se-
quence of the skeletal muscle enhancer, located 7 kbp up-
stream of the mouse cardiac actin gene, revealed a novel com-
plex which is important for activity. Interaction with DNA
depends on the presence of a novel longer form of Emb, a
POU domain protein belonging to the POU VI subclass (42).
The myogenic factor MEF2D and the histone transacetylase
p300 form a complex with Emb. Another POU domain pro-
tein, Oct1, binds to an adjacent site.
The role of Oct1 in muscle gene regulation is not clear. It is
widely expressed, including in striated muscle, and it has been
identified as having a binding activity for a number of AT-rich
regulatory regions implicated in the expression of muscle
genes. The skeletal muscle enhancer of the M-CPK gene has an
AT-rich sequence, in addition to the consensus MEF2 site,
which binds the Mhox homeodomain protein. Oct1 and MEF2
also bind to this sequence. Mutagenesis, which disrupted each
of these binding activities separately, established that only
MEF2 is functionally necessary for reporter gene expression in
C2 myotubes (10). Both Oct1 and MEF2 bind to two regula-
tory sites in the promoter region of the IIB myosin heavy chain
gene (28). Binding appears to be cooperative, but the func-
tional requirement for Oct1, in addition to MEF2, was not
established. The cardiac Troponin 1 promoter also has an AT-
rich site, required for expression in cardiomyocytes. Here
again, MEF2 and Oct1 bind as separate protein-DNA com-
plexes; the role of the latter, relative to MEF2, which was
shown to transactivate the promoter, is not clear (13). In the
case of the AT-rich sequence of the cardiac actin enhancer,
FIG. 5. Identification of a protein contained in the nuclear extracts of C2 myoblasts and myotubes that is related to Emb. (A) Western blot
analysis in which 10 g of protein was loaded in each lane. After migration, the proteins were transferred to filters and probed with the antibody
directed against mPOU (the human Emb homologue) or the corresponding preimmune serum. A protein corresponding to a molecular mass of
80 kDa is detected specifically by the mPOU antibody in both myoblast and myotube nuclear extracts. The position of protein markers, run in
parallel, are indicated with an asterisk. (B) The published mPOU consensus site (CAGCTCATTATGATAATGAGGGGG) (62) was used as a
probe in gel shift experiments with nuclear extracts from C2 myotubes. Two major DNA-protein complexes were observed; the upper one contains
Oct1 and the lower Emb, as indicated by the interaction with these antibodies.  mPOU, anti-mPOU antibody;  Oct1, anti-Oct1 antibody.
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Oct1 binding to the site is weak, but this is probably due to
interference by Emb, since when Emb binding (as complex a)
is compromised with the shorter AT-rich sequence, Oct1 binds
strongly. Mutations which affect binding of Oct1 to the site did
not have an effect, although activity was slightly higher with a
perfect Oct1 site. This may reflect a positive effect of Oct1 on
the recruitment of other proteins to the site (41), although
complex b, for example, did not notably increase with this
mutant or with the shorter AT-rich sequence. There is promis-
cuity in the binding of Oct1 and Emb to their consensus se-
FIG. 6. Characterization of the DNA-protein complexes obtained on gel shift analysis with the 3 AT-rich DNA fragment as a probe and C2
myoblast nuclear extracts. (A) The addition of antibodies directed against three of the four MEF2 isoforms (A, B, and D), Oct1, and mPOU, the
human homologue of the POU protein Emb, revealed the presence of these proteins as indicated. (B) Competition experiments using an excess
of the 3 AT-rich sequence itself (AT-rich), the consensus site for Emb, the MEF2 binding site from the M-CPK enhancer, the Oct1 consensus site
from the H2B histone gene promoter, the so-called Mhox site from the M-CPK enhancer, and the MEF2 consensus site from the Troponin I gene
(TnI site). The consensus sites for the transcription factor PEA3, like that for Sp1, did not compete any of the DNA-protein complexes in gel shifts
(data not shown). (C) Gel shift experiment using as probe the IPOCT sequence (see Fig. 1A for the sequence), which shows one minor and one
major binding activity with myoblast nuclear extracts. These correspond to protein complexes b and d, respectively. The two complexes are
competed by preincubating the binding reaction with a 50- or 100-fold excess of cold IPOCT probe (Self50X, Self 100X) or with the entire AT-rich
3 fragment (AT rich). Complex d is competed by the Oct1 consensus site, while both the complexes are competed by an excess of the Emb
consensus site. Competition with the M-CPK MEF2 site (MEF2 cons) does not change the binding profile. Competition with the MHox sequence
mainly affects Oct1 binding, as expected. The addition of antibodies to Oct1 (Oct1) mainly shifts complex d, whereas the Emb antibody (mPOU)
mainly affects band b. An antibody to MEF2D (MEF2D) also eliminates band b.
2952 MOLINARI ET AL. MOL. CELL. BIOL.
quence (e.g., Fig. 5B; also see reference 42), so that it is
possible that Emb may also be implicated in some of the other
Oct1/MEF2 sites described.
Binding of MEF2 to the AT-rich sequence described here
appears to be indirect, via interaction with Emb. In fact, we
could not identify any consensus MEF2 site, although as seen
for the Mhox site in the M-CPK enhancer (10), MEF2 can bind
to some other AT-rich sequences. However, there is also no
competition with known MEF2 binding sites, and we therefore
conclude that MEF2 is present in a complex with Emb, which
renders it inaccessible for DNA binding. The DNA footprint
also points to DNA binding through Emb. No direct interac-
tion, as monitored by the yeast two-hybrid system or coimmu-
noprecipitation assays, was detectable between Emb and
MEF2D (data not shown), indicating that the interaction may
require DNA. Complexes a and b are seen with both myoblast
and myotube extracts. MEF2D is present already in dividing
myoblasts (4, 33), and in gel shift experiments with MEF2
antibodies, it is the antibody to this isoform which completely
shifts band b. Because of the position of band a at the top of
the gel, it is difficult to distinguish a shift; however, the bead
experiment, where MEF2D is as abundant as p300 in the
eluate, strongly suggests that it is also present in the large
complex a. This is also indicated by the ChIP experiment. The
3 AT-rich sequence alone does not enhance reporter gene
transcription with the proximal promoter. Functional assays
were carried out in the context of the larger enhancer se-
quence, which includes the E box, which is essential for activity
and binds myogenic factors of the MyoD family. These activate
muscle gene transcription in differentiating muscle cells only,
rendering the enhancer inactive in myoblasts. There is a
MEF2D isoform, which as a result of differential splicing has a
muscle-specific exon (33). In the absence of specific antibodies,
it was not possible to see if this is the form present in the
complex with Emb in myotubes. If this is so, then, like the more
ubiquitous MEF2D form present in myoblasts, it is not capable
of transactivating the enhancer alone. Other MEF2 isoforms,
such as MEF2C, accumulate in myotubes. MEF2C is also a
major isoform in cardiac muscle, and indeed, cardiac actin
gene expression is notably downregulated in the hearts of
MEF2C/ mutant mice (30), probably due to an essential
MEF2C binding site in a more proximal cardiac enhancer 5 to
this gene (M. Lemonnier and M. Buckingham, unpublished
data).
MEF2 does not appear to play a primary role as a transcrip-
tional transactivator of the cardiac actin enhancer but may
rather be instrumental at the level of chromatin remodeling.
MEF2 is known to interact with class II HDACs (35), and one
possibility was that a MEF2D/HDAC complex might prevent
premature expression of the cardiac actin gene in myoblasts or
in other cell types where MEF2D is expressed (4). However,
this is not the case, and it is the histone transacetylase p300
which is present in the large complex a, in both myoblasts and
myotubes. In vitro experiments have shown that p300 interacts
with MEF2C through the MADS box domain and that this
stimulates transactivation by this factor of skeletal muscle gene
regulatory sequences, such as the M-CPK enhancer (50). Such
MEF2-p300 interaction may also exert an effect through the
stabilization of essential MyoD/p300 complexes on adjacent
E-box sites (16). The increased immunoprecipitation by p300
FIG. 7. Further characterization of complex A. (A) Gel shift experiment with the labeled 3 AT-rich sequence incubated with a C2 myotube
nuclear extract, where antibodies () to HDAC4 or p300 were added as indicated to the binding reaction. (B) Gel shift experiment with this probe
and a C2 myoblast nuclear extract before (lane 1) or after (lane 2) passage over magnetic beads to which the same biotinylated sequence had been
bound. Lane 3 shows the gel shift given by an extract after the passage over magnetic beads without bound DNA. (C) Extracts before passage over
the beads (lane 1), after elution from beads to which the biotinylated sequence had been bound (lane 2), or after elution from the beads in the
absence of bound DNA (lane 3) were analyzed by Western blotting, using antibodies to MEF2D, p300, mPOU (Emb), and HDAC4. Bovine serum
albumin was added as a competitor for nonspecific protein binding in the bead experiment. It has a molecular weight similar to MEF2D’s, distorting
the MEF2D band on the Western blot (lane 2). (D) Extracts after elution from beads, in the absence of DNA (lane 1), in the presence of the
AT-rich biotinylated sequence (lane 2), or in the presence of a biotinylated AT-rich sequence mutated to abolish Emb binding (lane 3) were
analyzed by Western blotting with MEF2D, p300, and mPOU (Emb) antibodies, as in panel C.
VOL. 24, 2004 A NOVEL COMPLEX REGULATES THE MOUSE cardiac actin GENE 2953
FIG. 8. Chromatin immunoprecipitation of protein bound to the 3 AT-rich sequence of the cardiac actin enhancer. (A) This shows the results
of a real-time PCR experiment with the cardiac actin sequence and a neutral sequence from the PAH gene, not expressed in skeletal muscle,
amplified after chromatin immunoprecipitation with antibodies to mPOU, which recognizes Emb, MEF2D, and p300. (B) Autoradiography of a
gel in which the amplified products of the cardiac actin sequence have been separated. The control shown adjacent to the lane with the mPOU
antibody is without antibody. The control in the second series with p300 and MEF2D antibodies is the hemoagglutinin antibody, which gave results
similar to those with the control with no antibody. The lane marked input is the result obtained with chromatin after fixation and before
immunoprecipitation. (C) Summary of real-time PCR experiments with extracts from muscle cells at different stages, as proliferating myoblasts,
confluent cultures which are beginning to differentiate, and differentiated myotubes. The results are corrected with respect to the figures obtained
in the same experiment with the neutral PAH sequence. The controls in this series of experiments were -galactosidase or NFYB antibodies, which
gave results similar to those with the no-antibody control. The results are the average of at least three estimations.
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in the ChIP experiment, with extracts from differentiated myo-
tubes, probably reflects such a MyoD/p300 complex acting
through the essential E box. In the 3 sequence of the cardiac
actin enhancer, it is clear that MyoD, which can interact with
MEF2 in the absence of an E box (40), is not involved in the
MEF2/p300 complex. In cardiomyocytes, MEF2D has been
shown to interact with p300, and the MEF2 site where this
interaction takes place in the skeletal actin gene is essential for
expression both in cardiac cells in culture and in the heart (55).
As in other examples, p300 increases the transcriptional trans-
activation exerted by MEF2D. Interestingly, however, only
MEF2D, and not other MEF2 isoforms, appears to be capable
of interaction with p300 on MEF2 regulatory elements from a
number of muscle genes in this cardiac context. When overex-
pressed, MEF2 isoforms appear to function similarly, as in the
case of interaction with HDACs shown for MEF2A (29, 38) or
MEF2C (31, 60), and it is not clear how the isoforms differ
functionally. Both the results of Slepak et al. (55) and those
reported here for the cardiac actin sequence suggest a prefer-
ential interaction of p300 with MEF2D in both cardiac and
skeletal muscle cells. It has been shown that inhibition of
p300/CBP in skeletal muscle cell cultures prevents the expres-
sion of genes encoding structural muscle proteins, such as
myosins and actins (44), but does not affect the first stages of
differentiation, such as the p21-mediated block to cell cycling
or activation of the myogenic regulatory factor myogenin,
which depend on another histone acetyltransferase, PCAF
(47). The PCAF gene is not an essential gene in mice, but in
embryos with a null mutation in the gene for the related his-
tone acetyltransferase, GCN5, skeletal muscle formation is
compromised (65). p300/ mutant mice die during embryo-
genesis due to severe cardiac defects (67).
The Emb protein is a component of complexes a and b.
DNA footprinting and competition experiments show that it
binds to the AT-rich sequence, to a motif, TATTTCTATA
ATG, which is similar to the central motif TATTA TAAT
described for the rat protein Brn5 (49) or ATTA(N)3TAAT
for the human mPOU protein (63). Mutation of the 3 TAAT
part of the motif, in particular, affects activity of the enhancer.
Mutation of the 5 ATTT has less effect, but this may be
because there are AT-rich sequences immediately upstream;
AAAT(N)7TAAT and TAAT(N) 7TAAT are also preferred
binding sites (63). Given the conservation of POU specific and
POU homeo domains, it is probable that Emb, like Oct1 (58),
contacts the AT-rich motifs through these two protein domains,
which are connected by a flexible linker sequence. Brn5 (Emb),
again like Oct1, probably binds as a homodimer; the extended
DNA binding site, typical for POU proteins, makes it likely
that Emb can adopt multiple conformations (50). Indeed, the
two complexes seen with the cardiac actin AT-rich sequence,
namely, the minor complex Emb-MEF2D (b) and Emb-
MEF2D-p300 (a), may reflect this phenomenon. The Emb
protein identified in C2 muscle cell extracts and, after binding
to the 3 AT-rich sequence, on Western blots using an mPOU
antibody, migrates at about 80 kDa. This is twice the size
predicted on the basis of sequences generated from the single
Emb gene (42). The human mPOU (58) and rat Brn5 (1)
mRNA sequences, as previously described, would also code for
a protein of about 40 kDa. In zebrafish, a longer transcript,
encoding a 64-kDa form, has been identified (25). We have
carried out 5 rapid amplification of cDNA ends experiments
from the first exon of mouse Emb and found additional tran-
scripts, including a major species with an open reading frame
encoding a protein of about 80 kDa (48a). This protein con-
tains the POU domain characteristic of the POU VI class to
which Emb belongs, but it also has homology in the NH2 part
to bromodomain-containing proteins. This domain, which is
found in a number of transcriptional regulators involved in
chromatin remodeling, specifically binds to acetylated lysine
residues (11). These are generated by acetylation of histones,
and it is therefore possible that Emb, as well as p300 itself,
which has a bromodomain, interacts with histone tails, possibly
recognizing different features of the histone acetylation code
(58). Histone transacetylases may themselves be acetylated
(27), providing a possible mechanism for Emb-p300 interac-
tions. Tests of function with the shorter form of Emb have
given contradictory results, and its potential transcriptional
targets are ill defined. In vitro experiments with rat Brn5 (1) and
human TCF1/mPOU (36) suggest that it may act as a transcrip-
tional activator, while other experiments with human mPOU
might suggest repression, possibly by competition with Oct1
(62). Based on our observations, we would suggest that it is
involved in transcriptional activation, via chromatin remodel-
ing, and that this probably involves the NH2 domain, absent
from the shorter forms tested. Emb/Brn5/mPOU are expressed
in a number of adult tissues, including brain and striated mus-
cle (1, 36, 42, 62). Brn5 is high in postmitotic neurons, and
overexpression of the 40-kDa form has a negative effect on
proliferation, although it does not affect differentiation (8, 9).
It has also been detected in adult myelinating Schwann cells,
where its transcription is regulated by neuregulin (64). In the
mouse, in situ hybridization with an Emb probe detects tran-
scripts in the postimplantation embryo, especially in the central
nervous system (42). In another report (14), based on RNase
protection, Emb expression was found to be higher in em-
bryonic and fetal muscle and lower in the developing heart and
brain; in myogenin/ mutant embryos, Emb levels were not
affected, as might be expected given its presence in myoblasts.
In both adult and embryonic tissues where Emb transcripts
have been detected, the 80-kDa protein is accumulated (48a).
It is potentially interesting that MEF2, like Emb, is high in
brain and striated muscle, although MEF2D is detected in
many cell types (4).
The distal enhancer of the mouse cardiac actin gene is active
in embryonic skeletal muscle in vitro and in differentiating
skeletal muscle cell cultures (2, 3). However, in addition, the
presence of this upstream region renders transgene expression
more reproducible; indeed, in conjunction with the sequence
which also corresponds to a DNase I-hypersensitive site at 5
kbp from the gene, 100% of transgenes express correctly in
heart and skeletal muscle (3). In addition, displacement of the
distal enhancer by insertion of a partial duplication of the gene
results in low levels of cardiac actin in the heart as well as in
skeletal muscle (19). The DNase I-hypersensitive site at kbp
7 maps to the 3 end of the enhancer, where the AT-rich
sequence is located. Activation of the cardiac actin gene in
striated muscle may depend on an initial opening of chromatin
around the locus through the Emb-MEF2D-p300 complex,
which would already function in myoblasts, followed by acti-
vation of this and other enhancers by cardiac or skeletal muscle
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transcription factors as the cells differentiate. It is not clear in
this model, at present, how the initial chromatin remodeling is
restricted to striated muscle, since Emb, MEF2D, and p300 are
present in other tissues. However, it may depend on events
such as phosphorylation of MEF2D (35) or Emb (1) by con-
vergent signaling pathways, which would build in a tissue-spe-
cific response. Such remodeling of chromatin is also likely to
depend on a number of effectors, including, in skeletal muscle
precursors, the myogenic determination factors Myf5 and
MyoD (20). Other types of chromatin remodeling activities,
such as methylases and Swi/Snf complexes (58), are also likely
to be involved in rendering muscle genes susceptible to tran-
scription; the Emb-MEF2D-p300 complex described here is
one potential player in this complex process.
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